CPRX Quote, Financials, Valuation and Earnings

Karyopharm Therapeutics, Inc. has a net margin of 34.53% compared to Catalyst Pharmaceuticals, Inc.'s net margin of -299.89%. Catalyst Pharmaceuticals, Inc.'s return on equity of 25.2% beat Karyopharm Therapeutics, Inc.'s return on equity of --.

Catalyst Pharmaceuticals, Inc. has a consensus price target of $34.57, signalling upside risk potential of 49.79%. On the other hand Karyopharm Therapeutics, Inc. has an analysts' consensus of $15.33 which suggests that it could grow by 63.99%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than Catalyst Pharmaceuticals, Inc., analysts believe Karyopharm Therapeutics, Inc. is more attractive than Catalyst Pharmaceuticals, Inc..

Catalyst Pharmaceuticals, Inc. has a beta of 0.735, which suggesting that the stock is 26.455% less volatile than S&P 500. In comparison Karyopharm Therapeutics, Inc. has a beta of 0.208, suggesting its less volatile than the S&P 500 by 79.163%.

Catalyst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Karyopharm Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Karyopharm Therapeutics, Inc. pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals, Inc. quarterly revenues are $152.6M, which are larger than Karyopharm Therapeutics, Inc. quarterly revenues of $34.1M. Catalyst Pharmaceuticals, Inc.'s net income of $52.7M is higher than Karyopharm Therapeutics, Inc.'s net income of -$102.2M. Notably, Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio is 13.70x while Karyopharm Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals, Inc. is 4.99x versus 0.70x for Karyopharm Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of 34.53% compared to Catalyst Pharmaceuticals, Inc.'s net margin of 47.99%. Catalyst Pharmaceuticals, Inc.'s return on equity of 25.2% beat Krystal Biotech, Inc.'s return on equity of 19.22%.

Catalyst Pharmaceuticals, Inc. has a consensus price target of $34.57, signalling upside risk potential of 49.79%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $313.22 which suggests that it could grow by 13.34%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..

Catalyst Pharmaceuticals, Inc. has a beta of 0.735, which suggesting that the stock is 26.455% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.493, suggesting its less volatile than the S&P 500 by 50.719%.

Catalyst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals, Inc. quarterly revenues are $152.6M, which are larger than Krystal Biotech, Inc. quarterly revenues of $107.1M. Catalyst Pharmaceuticals, Inc.'s net income of $52.7M is higher than Krystal Biotech, Inc.'s net income of $51.4M. Notably, Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio is 13.70x while Krystal Biotech, Inc.'s PE ratio is 40.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals, Inc. is 4.99x versus 21.25x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals, Inc. has a net margin of 34.53% compared to Catalyst Pharmaceuticals, Inc.'s net margin of 40.17%. Catalyst Pharmaceuticals, Inc.'s return on equity of 25.2% beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.

Catalyst Pharmaceuticals, Inc. has a consensus price target of $34.57, signalling upside risk potential of 49.79%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.60 which suggests that it could grow by 44.5%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Rigel Pharmaceuticals, Inc..

Catalyst Pharmaceuticals, Inc. has a beta of 0.735, which suggesting that the stock is 26.455% less volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.111, suggesting its more volatile than the S&P 500 by 11.137%.

Catalyst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals, Inc. quarterly revenues are $152.6M, which are larger than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. Catalyst Pharmaceuticals, Inc.'s net income of $52.7M is higher than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio is 13.70x while Rigel Pharmaceuticals, Inc.'s PE ratio is 5.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals, Inc. is 4.99x versus 2.33x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics Corp. has a net margin of 34.53% compared to Catalyst Pharmaceuticals, Inc.'s net margin of 46.1%. Catalyst Pharmaceuticals, Inc.'s return on equity of 25.2% beat United Therapeutics Corp.'s return on equity of 19.56%.

Catalyst Pharmaceuticals, Inc. has a consensus price target of $34.57, signalling upside risk potential of 49.79%. On the other hand United Therapeutics Corp. has an analysts' consensus of $564.64 which suggests that it could grow by 11.28%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than United Therapeutics Corp..

Catalyst Pharmaceuticals, Inc. has a beta of 0.735, which suggesting that the stock is 26.455% less volatile than S&P 500. In comparison United Therapeutics Corp. has a beta of 0.854, suggesting its less volatile than the S&P 500 by 14.572%.

Catalyst Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals, Inc. pays -- of its earnings as a dividend. United Therapeutics Corp. pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals, Inc. quarterly revenues are $152.6M, which are smaller than United Therapeutics Corp. quarterly revenues of $790.2M. Catalyst Pharmaceuticals, Inc.'s net income of $52.7M is lower than United Therapeutics Corp.'s net income of $364.3M. Notably, Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio is 13.70x while United Therapeutics Corp.'s PE ratio is 18.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals, Inc. is 4.99x versus 7.58x for United Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.